返回
Coronary Microvascular Dysfunction
DOI:10.1161/ATVBAHA.121.316025.png)
摘要
En 中文
Over the past couple of decades, accumulating evidence has shown that structural and functional abnormalities of coronary microvasculature are highly prevalent, associated with adverse clinical outcomes in patients with various cardiovascular diseases. The term coronary microvascular dysfunction (CMD) has been coined to refer to this clinical condition and is increasingly recognized as an important clinical entity in many clinical settings. The potential mechanisms of CMD appear to be heterogenous, including enhanced coronary vasoconstrictive reactivity at microvascular level, impaired endothelium-dependent and independent coronary vasodilator capacities, and increased coronary microvascular resistance secondary to structural factors. Recent experimental and clinical studies have highlighted emerging modulators of vascular functions, vital insight into the pathogenesis of cardiovascular diseases associated with CMD, and potential therapeutic interventions to CMD with major clinical implications. In this article, we will briefly review the current progress on pathophysiology, molecular mechanisms, and clinical management of CMD from bench to bedside.
Keyword:
cardiovascular diseases
coronary artery disease
endothelium
microcirculation
期刊
IF:
7.4
论文数:
1.2W
被引数:
3.5W
机构
引用论文
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
LANCET
IF88.5
Systemic microvascular dysfunction in microvascular and vasospastic angina微血管和血管痉挛性心绞痛的全身微血管功能障碍
EUROPEAN HEART JOURNAL
IF35.6

